Latest Commercial Launch News

InFocus Group Holdings is streamlining its software development operations by divesting Prodigy9 and consolidating under Onify, aiming for immediate cost savings and a leaner, AI-native delivery model.

Yojee Limited has secured Wayfinder Cargo Solutions as its second commercial customer for the MOSAIC freight forwarding platform, marking full operational coverage across all freight modes and directions ahead of its full commercial launch.

Memphasys has inked its first exclusive commercialization agreement in South-East Asia with TMSC Vietnam, targeting the fast-growing Vietnamese IVF sector with its Felix™ sperm separation system. The two-year contract, valued at A$530,000, hinges on regulatory approval expected by August 2026.

EMVision's First Responder Brain Scanner has proven its operational feasibility in aeromedical settings with the Royal Flying Doctor Service, de-risking rural stroke diagnosis and supporting progression to commercial production.

Aguia Resources has received official commercialisation approval for its Pampafos phosphate fertiliser project, enabling invoicing and marketing ahead of a targeted sales campaign designed to boost cash flow by mid-2026.

Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

AoFrio’s first quarter revenue plunged 28% year-on-year, weighed down by the loss of a major US motor customer amid tariffs. The refrigeration tech firm is banking on new IoT product launches in Q2 to stabilise sales and improve profitability over 2026.

BPH Global inks binding deal with Temasek Innovation Holdings to validate its seaweed-based male vitality product through targeted biological assays, advancing regulatory and commercial ambitions.

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.